Francis Knuettel II, CFO of Pelthos Therapeutics Inc. (NASDAQ:PTHS), reported selling 1,500 shares of common stock for approximately $40,264 on May 22, 2026.
The shares were sold by the Lara Knuettel Revocable Trust in multiple open market trades at prices ranging from $26.66 to $27.16 per share. The stock closed at $27.17.
Despite the company's 180% return over the past year, Bond.az analysis suggests the stock remains undervalued.
As part of a separation agreement, Knuettel forfeited 13,947 unvested RSUs. However, 19,525 RSUs accelerated vesting and became fully vested.
He also saw accelerated vesting of 59,500 stock options and forfeited 42,500 options. Knuettel now holds 19,525 shares and 59,500 options.
In other news, Pelthos reported Q1 2026 earnings below expectations.
